Calmark signs distributor agreement with Enox Pharma for five key markets in the Middle East

Report this content

Calmark Sweden AB (publ) has today entered an exclusive distributor agreement with the company Enox Pharma AB regarding marketing and sales of Calmark's products in the countries Egypt, Iraq, Bahrain, Saudi Arabia and the United Arab Emirates. Through this agreement, Calmark expands its launch in the MENA region, where there is an extensive need for safe and effective diagnostics.

Enox Pharma is a Swedish company specializing in the distribution of life science products and related services between Europe and the MENA region. The company sells innovative, sustainable and efficient solutions with the goal of optimizing healthcare in the Middle East. Enox Pharma has established relationships with influential persons in clinics and hospitals in these countries, which is important for Calmark's upcoming launch work.

“The MENA market has a large population and enormous potential for both our Neo products and our Covid19 product. This agreement is an important milestone in our global sales strategy ", says Anna Söderlund, CEO of Calmark. "We are very pleased to sign an agreement with such a large distributor, who can launch our products in several countries."

”Our mission is to offer the healtcare sector in the MENA region the most innovative life-science products and services from the best sources at a reasonable cost”, says Kefah Esmael, CEO and co-founder of Enox Pharma, ”We are very happy for the new agreement with Calmark, there is a great need for both the Neo and Covid tests!”

“Enox Pharma is a company with solid knowledge and expertise about each individual country's cultural and commercial conditions. Through the agreement, we take a grip of this large region", says Magdalena Tharaldsen, Director International Business Development at Calmark. "I have high expectations and look forward to collaborating with the team at Enox Pharma!"

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-03-2021 16:40 CET.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at  




Documents & Links